Login to Your Account



Clinic roundup


Friday, March 21, 2014
Synta Pharmaceuticals Corp., of Lexington, Mass., said interim results from the ENCHANT-1 trial, a single-arm multicenter phase II proof-of-concept study designed to evaluate ganetespib, administered as a monotherapy for the treatment of metastatic breast cancer, were presented at the European Breast Cancer conference in Glasgow, Scotland.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription